{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:01:51Z","timestamp":1790622111766,"version":"4.1.0"},"reference-count":13,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,5,27]],"date-time":"2015-05-27T00:00:00Z","timestamp":1432684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aust J Dermatology"],"published-print":{"date-parts":[[2016,8]]},"abstract":"Abstract<\/jats:title>Background\/Objectives<\/jats:title>Maculo\u2010papular drug exanthema (MPE<\/jats:styled-content>) is the most common type of cutaneous adverse drug reaction (CAR<\/jats:styled-content>). Exanthematous macules and papules may also be the initial presentation of severe CAR<\/jats:styled-content> (SCAR<\/jats:styled-content>). We aimed to identify characteristics associated with the diagnosis of SCAR<\/jats:styled-content> in CAR<\/jats:styled-content>\u2010hospitalised patients.<\/jats:p><\/jats:sec>Methods<\/jats:title>This cross\u2010sectional study was performed in a tertiary hospital in C<\/jats:styled-content>hile. All CAR<\/jats:styled-content> patients who were initially evaluated for exanthematous macules and papules were assessed for clinical, laboratory and pathological variables and these were contrasted with MPE<\/jats:styled-content> or SCAR<\/jats:styled-content> diagnosis at discharge.<\/jats:p><\/jats:sec>Results<\/jats:title>We enrolled 86 patients, of whom 25 (29%) had an at\u2010discharge diagnosis of SCAR<\/jats:styled-content>. SCAR<\/jats:styled-content> patients were younger and the latency (time from starting drug to development of first skin lesions) was longer than in MPE<\/jats:styled-content> patients: 43.6\u2009\u00b1\u200918.7 years versus 54.0\u2009\u00b1\u200921.8 years (P<\/jats:italic>\u2009=\u20090.039) and 14 days; range 1 to 35, versus 7 days; range 1 to 45 (P<\/jats:italic>\u2009=\u20090.001). The presence of cutaneous pain (OR<\/jats:styled-content> 7.4 95% CI<\/jats:styled-content> 1.3\u201341), mucosal involvement (OR<\/jats:styled-content> 9.5 CI<\/jats:styled-content> 95% 2.6\u2013 34.5) and anticonvulsant use (OR<\/jats:styled-content> 6.11 95% CI<\/jats:styled-content> 1.91\u201319.53) were significantly associated with SCAR<\/jats:styled-content> at discharge. Antibiotics use was significantly associated with MPE<\/jats:styled-content> diagnosis (OR<\/jats:styled-content> 2.8 95% CI<\/jats:styled-content> 1.1\u20137.6). These six variables together explain 45% of the risk of having SCAR<\/jats:styled-content> (R2\u2009=\u20090.449). None of the early laboratory or pathological variables was associated with SCAR<\/jats:styled-content>.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>In hospitalised patients assessed for exanthematous macules and papules, the evaluation of these clinical features may aid in the early identification of SCAR<\/jats:styled-content> cases.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajd.12347","type":"journal-article","created":{"date-parts":[[2015,5,27]],"date-time":"2015-05-27T13:03:22Z","timestamp":1432731802000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Progression of drug exanthemas to serious drug eruptions: A retrospective review identifying early determinants"],"prefix":"10.1111","volume":"57","author":[{"given":"Juan","family":"Manriquez","sequence":"first","affiliation":[{"name":"Department of Dermatology Pontificia Universidad Catolica de Chile Santiago Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"Andino\u2010Navarrete","sequence":"additional","affiliation":[{"name":"Department of Dermatology Pontificia Universidad Catolica de Chile Santiago Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Cataldo\u2010Cerda","sequence":"additional","affiliation":[{"name":"Department of Dermatology Pontificia Universidad Catolica de Chile Santiago Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Downey","sequence":"additional","affiliation":[{"name":"Department of Dermatology Pontificia Universidad Catolica de Chile Santiago Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Berroeta","sequence":"additional","affiliation":[{"name":"Department of Dermatology Pontificia Universidad Catolica de Chile Santiago Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,5,27]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2004.12.022"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08156.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07704.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.2332\/allergolint.55.9"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000354918"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2000.00061.x"},{"key":"e_1_2_7_9_1","first-page":"30","article-title":"Does hypernatremia impact mortality in toxic epidermal necrolysis?","volume":"8","author":"Namdar T","year":"2010","journal-title":"Ger. Med. Sci."},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000148255"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/0885066610390466"},{"key":"e_1_2_7_12_1","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1684\/ejd.2011.1550","article-title":"Identifying prognostic factors for drug rash with eosinophilia and systemic symptoms (DRESS)","volume":"21","author":"Wei CH","year":"2011","journal-title":"Eur. J. Dermatol."},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083849"},{"key":"e_1_2_7_14_1","first-page":"247","article-title":"Symptomatology and markers of the severity of erythematous drug eruptions","volume":"126","author":"Dijen V","year":"1999","journal-title":"Ann. Dermatol. Venereol."}],"container-title":["Australasian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajd.12347","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajd.12347","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T11:52:36Z","timestamp":1695556356000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajd.12347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,27]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.1111\/ajd.12347"],"URL":"https:\/\/doi.org\/10.1111\/ajd.12347","archive":["Portico"],"relation":{},"ISSN":["0004-8380","1440-0960"],"issn-type":[{"value":"0004-8380","type":"print"},{"value":"1440-0960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,27]]},"assertion":[{"value":"2014-10-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-04-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-05-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}